Similar articles for PMID: 22588463

Year	Number of Results
1997	1
1998	2
2000	2
2001	3
2002	3
2003	2
2004	1
2005	7
2006	5
2007	7
2008	11
2009	7
2010	6
2011	7
2012	11
2013	7
2014	9
2015	8
2016	7
2017	3
2018	3
2019	4
2020	5
2021	6
2023	2
2024	0

1

Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.

Ait-Oudhia S, Straubinger RM, Mager DE. Ait-Oudhia S, et al. Pharm Res. 2012 Oct;29(10):2833-44. doi: 10.1007/s11095-012-0775-8. Epub 2012 May 17. Pharm Res. 2012. PMID: 22588463

2

Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy.

Ait-Oudhia S, Straubinger RM, Mager DE. Ait-Oudhia S, et al. J Pharmacol Exp Ther. 2013 Jan;344(1):103-12. doi: 10.1124/jpet.112.199109. Epub 2012 Oct 31. J Pharmacol Exp Ther. 2013. PMID: 23115220 Free PMC article.

3

Pharmacokinetics of paclitaxel-containing liposomes in rats.

Fetterly GJ, Straubinger RM. Fetterly GJ, et al. AAPS PharmSci. 2003 Nov 21;5(4):E32. doi: 10.1208/ps050432. AAPS PharmSci. 2003. PMID: 15198520 Free PMC article.

4

Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.

Tsushima T, Kasai H, Tanigawara Y. Tsushima T, et al. Cancer Chemother Pharmacol. 2020 Oct;86(4):487-495. doi: 10.1007/s00280-020-04140-x. Epub 2020 Sep 15. Cancer Chemother Pharmacol. 2020. PMID: 32930844

5

Paclitaxel and its formulations.

Singla AK, Garg A, Aggarwal D. Singla AK, et al. Int J Pharm. 2002 Mar 20;235(1-2):179-92. doi: 10.1016/s0378-5173(01)00986-3. Int J Pharm. 2002. PMID: 11879753 Review.

6

Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.

Zhou R, Mazurchuk RV, Tamburlin JH, Harrold JM, Mager DE, Straubinger RM. Zhou R, et al. J Pharmacol Exp Ther. 2010 Feb;332(2):479-88. doi: 10.1124/jpet.109.160044. Epub 2009 Oct 27. J Pharmacol Exp Ther. 2010. PMID: 19861574 Free PMC article.

7

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.

Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Cancer Chemother Pharmacol. 2009 May;63(6):1035-48. doi: 10.1007/s00280-008-0828-1. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791717 Clinical Trial.

8

Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.

Gill KK, Nazzal S, Kaddoumi A. Gill KK, et al. Eur J Pharm Biopharm. 2011 Oct;79(2):276-84. doi: 10.1016/j.ejpb.2011.04.017. Epub 2011 May 7. Eur J Pharm Biopharm. 2011. PMID: 21575719

9

Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.

Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR. Fetterly GJ, et al. Clin Cancer Res. 2008 Sep 15;14(18):5856-63. doi: 10.1158/1078-0432.CCR-08-1046. Clin Cancer Res. 2008. PMID: 18794097 Clinical Trial.

10

Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.

Nornoo AO, Chow DS. Nornoo AO, et al. Int J Pharm. 2008 Feb 12;349(1-2):117-23. doi: 10.1016/j.ijpharm.2007.07.043. Epub 2007 Aug 7. Int J Pharm. 2008. PMID: 17869458

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

107 results

Results by year